Great Point Partners LLC bought a new stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,559,000 shares of the company’s stock, valued at approximately $3,491,000. Unicycive Therapeutics accounts for 1.0% of Great Point Partners LLC’s holdings, making the stock its 24th largest position. Great Point Partners LLC owned about 9.07% of Unicycive Therapeutics as of its most recent SEC filing.
Separately, Bleakley Financial Group LLC acquired a new position in Unicycive Therapeutics during the 3rd quarter worth $33,000. Institutional investors own 40.42% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on UNCY. HC Wainwright reissued a “buy” rating and set a $2.50 target price on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $5.13.
Unicycive Therapeutics Price Performance
NASDAQ UNCY opened at $0.59 on Wednesday. The company’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $0.52. Unicycive Therapeutics, Inc. has a twelve month low of $0.20 and a twelve month high of $1.82.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Recommended Stories
- Five stocks we like better than Unicycive Therapeutics
- What to Know About Investing in Penny Stocks
- Gold vs. Silver: Profit Opportunities in the Widening Spread
- With Risk Tolerance, One Size Does Not Fit All
- Semler Stock Surges Over 130% in November: A New Bitcoin Play?
- Roth IRA Calculator: Calculate Your Potential Returns
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
Want to see what other hedge funds are holding UNCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report).
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
